8-K - Bruker Corporation | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Bruker Corporation appointed Thierry L. Bernard, CEO of QIAGEN N.V., to its Board of Directors effective April 1, 2026, expanding the board to twelve members.

Key Takeaways

1Thierry L. Bernard appointed as new director, effective April 1, 2026, expanding board to twelve members.

2Bernard currently serves as CEO of QIAGEN N.V. and will step down upon successor appointment.

3His director compensation will align with other non-employee directors as per 2025 proxy statement.

4Bernard brings decades of life-science tools and diagnostics industry leadership experience.

5Committee assignments will be disclosed in a future amended Form 8-K.

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Electio

Management Change

Chief Executive Officer in March 2020 after s

9.01

. Financial Statements and Exhibits. Exhibits.: Number | Col4: Description Exhibits.: 99.1 | Col4: Press release dated April 1, 2026. Exhibits.: 104 | Col4: Cov

Exhibits Only

Source Document

Executive & Director Changes

Thierry L. Bernard

Director

Appointed

Effective: 2026-04-01

Board expansion to twelve directors

Exhibits (2)

8-K

99.1

EX-99.1